Markets:

Overview

News

Currencies

International

Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

105.08 -0.87 (-0.82%)

Streaming Delayed Price Updated: 11:34 AM EDT, Aug 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug ↗

September 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...

Via Benzinga

Mirum, Takeda Ink Maralixibat Licensing Pact In Japan ↗

September 21, 2021

Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and Takeda Pharmaceutical Company Limited (NYSE: TAK) have entered into an exclusive licensing agreement for...

Via Benzinga

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO ↗

August 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗

July 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...

Via Benzinga

Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan

September 21, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

What 5 Analyst Ratings Have To Say About Mirum Pharmaceuticals ↗

September 20, 2021

Within the last quarter, Mirum Pharmaceuticals (NASDAQ:MIRM) has observed ...

Via Benzinga

Mirum Pharmaceuticals Submits European Marketing Authorization Application for Maralixibat in Alagille Syndrome Supported by New Positive Results from Natural History Study Comparison

September 13, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 10, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Participate in September Investor Conferences

September 02, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates ↗

August 31, 2021

August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New...

Via Benzinga

Mirum Pharmaceuticals Appoints Biotechnology Executive William C. Fairey to its Board of Directors

August 19, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 10, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

August 05, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021

July 29, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharma Out-Licenses Maralixibat Rights To GC Pharma in South Korea ↗

July 27, 2021

Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and GC Pharma have entered into an exclusive licensing agreement to develop and commercialize Mirum's maralixibat...

Via Benzinga

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗

August 01, 2021

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....

Via Benzinga

The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs ↗

July 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

July 27, 2021

During Tuesday's morning session, 216 companies made new 52-week lows. Noteworthy Points: Alibaba Group Holding (NYSE:BABA) was the largest firm by market cap...

Via Benzinga

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts ↗

July 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI...

Via Benzinga

Mirum Pharmaceuticals and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South Korea

July 26, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 12, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Present at Piper Sandler’s Virtual EASL Takeaway Day

June 24, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Presents Analyses From Its Rare Liver Disease Programs at the EASL International Liver Congress 2021

June 23, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Showcase Analyses From Its Rare Liver Disease Programs at The International Liver Congress 2021

June 16, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 10, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. to Board of Directors

June 07, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Showcases Maralixibat Transplant-Free Survival Data for Progressive Familial Intrahepatic Cholestasis and Long-Term Safety Analyses for Alagille Syndrome during WCPGHAN Annual Meeting

June 03, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition (WCPGHAN) Annual Meeting 2021

May 26, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 10, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

May 06, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.